Comparative Pharmacology
Head-to-head clinical analysis: APONVIE versus CLOPRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APONVIE versus CLOPRA.
APONVIE vs CLOPRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
APONVIE (pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor. It binds to and inhibits FGFR1, FGFR2, and FGFR3, thereby suppressing FGFR signaling and reducing proliferation and survival of tumor cells with FGFR alterations.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and a 5-HT4 receptor agonist, enhancing gastrointestinal motility and having antiemetic effects via central and peripheral actions.
APONVIE is not a recognized drug; no dosing information available.
Clopra (metoclopramide) 10 mg orally or intramuscularly 30 minutes before meals and at bedtime; maximum 30 mg/day. For intravenous administration, give 10 mg over 1-2 minutes.
None Documented
None Documented
Clinical Note
moderateMetoclopramide + Haloperidol
"The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol."
Clinical Note
moderateMetoclopramide + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Metoclopramide."
Clinical Note
moderateMetoclopramide + Cyclosporine
"Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects."
Clinical Note
moderateTerminal elimination half-life is approximately 12 hours in healthy adults; prolonged to 24–36 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life 6-8 hours (prolonged in renal impairment; up to 20 hours in severe CKD)
APONVIE is primarily excreted renally as unchanged drug (approx. 70%) and via biliary/fecal routes (approx. 30%).
Renal (50-70% as unchanged drug and metabolites); fecal (20-30%); biliary (minor ~5%)
Category C
Category C
Antiemetic
Antiemetic/Prokinetic Agent
Metoclopramide + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Metoclopramide."